Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YAMATO trial of afatinib-to-osimertinib switch versus osimertinib first-line therapy in EGFR-mutant advanced NSCLC
jRCTs031200021Phase 2Completed
- Sponsor
- Japan Thoracic Oncology Research Group
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Afatinib then osimertinib with Osimertinib (2 arms). Primary endpoint: 2-year progression-free survival. Started May 2020; status: completed.
02
Drugs
afatinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031200021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200021.